Martin Huelsmann
Univ.Clinic II, Medical University Vienna · Medical university Vienna, Department of Cardiology · Medical University of Vienna
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Martin Huelsmann as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:24 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT02817360 · NT-proBNP Selected Prevention of Cardiac Events in Diabetic PatientsMartin Huelsmann · recruiting · Heart Diseases, Diabetes Mellitus, Type 2 · principal investigator
- Ph3NCT00610051 · ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart FailureBiopeutics Co., Ltd · not yet recruiting · End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, NYHF Class III-IV · principal investigator
- N/ANCT00437866 · Hepcidin in Anemic Chronic Heart Failure (CHF) PatientsMedical University of Vienna · completed · Anemia, Chronic Heart Failure · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:24 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial.J Am Coll Cardiol · 2013315 citationsRCR 8.8
- N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.J Am Coll Cardiol · 2010191 citationsRCR 5.0
- Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.Acta Anaesthesiol Scand · 200370 citationsRCR 1.8
- Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.Eur J Heart Fail · 200744 citationsRCR 1.3
- Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care.Eur J Clin Invest · 201139 citationsRCR 1.3
- Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.Eur J Heart Fail · 200534 citationsRCR 1.0
- Polyunsaturated fatty acids supplementation impairs anti-oxidant high-density lipoprotein function in heart failure.Eur J Clin Invest · 201811 citationsRCR 0.6
- B-type natriuretic peptide predicts benefit from a home-based nurse care in chronic heart failure.J Card Fail · 20098 citationsRCR 0.3
- 3 citationsRCR 0.1